https://www.onhealthcare.tech/p/one-infusion-a-permanent-gene-editThoughts on Healthcare Markets & Technologyen2026-05-28T11:02:47+00:00One Infusion. A Permanent Gene Edit. A Lifetime of LDL Lowering. The VERVE-102 NEJM Data, the Lilly Acquisition Thesis, and What It Means.https://www.onhealthcare.tech/p/part-ii-one-infusion-a-permanentThoughts on Healthcare Markets & Technologyen2026-05-28T01:14:59+00:00Part II: One Infusion. A Permanent Gene Edit. A Lifetime of LDL Lowering. The VERVE-102 NEJM Data, the Lilly Acquisition Thesis, and What It Means.https://www.onhealthcare.tech/p/part-i-one-infusion-a-permanent-geneThoughts on Healthcare Markets & Technologyen2026-05-28T01:13:01+00:00Part I: One Infusion. A Permanent Gene Edit. A Lifetime of LDL Lowering. The VERVE-102 NEJM Data, the Lilly Acquisition Thesis, and What It Means.https://www.onhealthcare.tech/p/mark-cubans-10plan-then-and-now-from-b2bThoughts on Healthcare Markets & Technologyen2026-05-27T16:01:08+00:00Mark Cuban’s 10Plan, Then and Now: From the 2019 RAND-Modeled Self-Pay Concept to the 2026 Bank Account Reboot, and What It Would Actually Mean for Insurers and the ACA Risk Poolhttps://www.onhealthcare.tech/p/mark-cubans-10plan-then-and-now-fromThoughts on Healthcare Markets & Technologyen2026-05-27T15:51:47+00:00Mark Cuban’s 10Plan, Then and Now: From the 2019 RAND-Modeled Self-Pay Concept to the 2026 Bank Account Reboot, and What It Would Actually Mean for Insurers and the ACA Risk Pool